Scott Hunter

Mr. Hunter has more than 15 years of eye care industry experience focused on therapies spanning ocular inflammation and pain, bacterial conjunctivitis, glaucoma and uveitis. Prior to joining Shire, Mr. Hunter served as director of marketing at Bausch + Lomb where he was responsible for their Lotemax franchise and successfully launching top selling anti-inflammatory therapies (Prolensa and Lotemax Gel). Mr. Hunter started his career in clinical research where he was part of project teams that brought to market novel ophthalmic therapeutics such as Retisert and Besivance. Mr. Hunter holds a BS in biology from the University of South Florida, an MBA from the University of Tampa, and an MS in pharmaceutical economics from the University of Florida.